Fluctuating expression of miR-584 in primary and high-grade gastric cancer.
Adult
Aged
Biomarkers, Tumor
/ metabolism
Case-Control Studies
Computational Biology
Down-Regulation
Female
Gastric Mucosa
/ microbiology
Gene Expression Regulation, Neoplastic
Helicobacter Infections
/ diagnosis
Helicobacter pylori
/ isolation & purification
Host-Pathogen Interactions
/ genetics
Humans
Kaplan-Meier Estimate
Male
MicroRNAs
/ metabolism
Middle Aged
Neoplasm Grading
Prognosis
RNA-Seq
STAT1 Transcription Factor
/ genetics
Stomach Neoplasms
/ diagnosis
Survival Rate
Up-Regulation
Computational analysis
Gastric cancer
Helicobacter pylori
miR-584
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
02 Jul 2020
02 Jul 2020
Historique:
received:
28
10
2019
accepted:
25
06
2020
entrez:
4
7
2020
pubmed:
4
7
2020
medline:
30
1
2021
Statut:
epublish
Résumé
Gastric cancer is the fifth most common cancer worldwide. Along with environmental factors, such as Helicobacter pylori (H. pylori) infection, genetic changes play important roles in gastric tumor formations. miR-584 is a less well-characterized microRNA (miRNA), with apparent activity in human cancers. However, miR-584 expression pattern in gastric cancer development has remained unclear. This study aims to analyze the expression of miR-584 in gastric cancer samples and investigates the associations between this miRNA and H. pylori infection and clinical characteristics. The expression level of miR-584 was studied in primary gastric cancers versus healthy control gastric mucosa samples using the RT-qPCR method. The clinical data were analyzed statistically in terms of miR-584 expression. In silico studies were employed to study miR-584 more broadly in order to assess its expression and find new potential target genes. Both experimental and in silico studies showed up-regulation of miR-584 in patients with gastric cancer. This up-regulation seems to be induced by H. pylori infection since the infected samples showed increased levels of miR-584 expression. Deeper analyses revealed that miR-584 undergoes a dramatic down-regulation in late stages, invasive and lymph node-metastatic gastric tumors. Bioinformatics studies demonstrated that miR-584 has a substantial role in cancer pathways and has the potential to target STAT1 transcripts. Consistent with the inverse correlation between TCGA RNA-seq data of miR-584 and STAT1 transcripts, the qPCR analysis showed a significant negative correlation between these two RNAs in a set of clinical samples. miR-584 undergoes up-regulation in the stage of primary tumor formation; however, becomes down-regulated upon the progression of gastric cancer. These findings suggest the potential of miR-584 as a diagnostic or prognostic biomarker in gastric cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Gastric cancer is the fifth most common cancer worldwide. Along with environmental factors, such as Helicobacter pylori (H. pylori) infection, genetic changes play important roles in gastric tumor formations. miR-584 is a less well-characterized microRNA (miRNA), with apparent activity in human cancers. However, miR-584 expression pattern in gastric cancer development has remained unclear. This study aims to analyze the expression of miR-584 in gastric cancer samples and investigates the associations between this miRNA and H. pylori infection and clinical characteristics.
METHODS
METHODS
The expression level of miR-584 was studied in primary gastric cancers versus healthy control gastric mucosa samples using the RT-qPCR method. The clinical data were analyzed statistically in terms of miR-584 expression. In silico studies were employed to study miR-584 more broadly in order to assess its expression and find new potential target genes.
RESULTS
RESULTS
Both experimental and in silico studies showed up-regulation of miR-584 in patients with gastric cancer. This up-regulation seems to be induced by H. pylori infection since the infected samples showed increased levels of miR-584 expression. Deeper analyses revealed that miR-584 undergoes a dramatic down-regulation in late stages, invasive and lymph node-metastatic gastric tumors. Bioinformatics studies demonstrated that miR-584 has a substantial role in cancer pathways and has the potential to target STAT1 transcripts. Consistent with the inverse correlation between TCGA RNA-seq data of miR-584 and STAT1 transcripts, the qPCR analysis showed a significant negative correlation between these two RNAs in a set of clinical samples.
CONCLUSION
CONCLUSIONS
miR-584 undergoes up-regulation in the stage of primary tumor formation; however, becomes down-regulated upon the progression of gastric cancer. These findings suggest the potential of miR-584 as a diagnostic or prognostic biomarker in gastric cancer.
Identifiants
pubmed: 32615958
doi: 10.1186/s12885-020-07116-5
pii: 10.1186/s12885-020-07116-5
pmc: PMC7345521
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN584 microRNA, human
0
MicroRNAs
0
STAT1 Transcription Factor
0
STAT1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
621Références
Aliment Pharmacol Ther. 2002 Apr;16 Suppl 2:145-57
pubmed: 11966535
Nat Methods. 2015 Aug;12(8):697
pubmed: 26226356
Genome Biol. 2015 Nov 27;16:265
pubmed: 26614063
Aliment Pharmacol Ther. 1999 Mar;13 Suppl 1:3-11
pubmed: 10209681
Cancer Causes Control. 2011 Nov;22(11):1497-502
pubmed: 21805052
Sci Rep. 2018 Jun 15;8(1):9227
pubmed: 29907753
Silence. 2011 Oct 25;2(1):7
pubmed: 22027184
Pathol Oncol Res. 2007;13(4):284-9
pubmed: 18158562
Nucleic Acids Res. 2014 Jan;42(Database issue):D78-85
pubmed: 24304892
PLoS One. 2013 Jun 10;8(6):e64707
pubmed: 23785404
J Biol Chem. 2013 Apr 26;288(17):11807-23
pubmed: 23479725
PLoS One. 2013;8(2):e56709
pubmed: 23437218
J Periodontol. 2014 Jun;85(6):e198-204
pubmed: 24228808
PLoS One. 2012;7(4):e35147
pubmed: 22536353
Cell Death Dis. 2016 Nov 24;7(11):e2480
pubmed: 27882939
FEBS Lett. 2012 Mar 23;586(6):722-8
pubmed: 22321642
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
J Endod. 2012 Jun;38(6):746-52
pubmed: 22595106
Lab Invest. 2008 Dec;88(12):1358-66
pubmed: 18794849
J Immunol. 2011 Oct 1;187(7):3578-86
pubmed: 21880981
J Clin Immunol. 2012 Apr;32(2):290-9
pubmed: 22161133
Oncotarget. 2016 Feb 23;7(8):8441-54
pubmed: 26870998
Nucleic Acids Res. 2014 Jan;42(Database issue):D92-7
pubmed: 24297251
J Exp Clin Cancer Res. 2017 Apr 21;36(1):59
pubmed: 28431583
IUBMB Life. 2012 Jul;64(7):628-35
pubmed: 22539488
Eur J Cancer. 2015 Jun;51(9):1164-87
pubmed: 24120180
Oncotarget. 2017 Jul 12;8(46):81572-81582
pubmed: 29113415
J Biol Chem. 2000 May 26;275(21):16064-72
pubmed: 10747974
Mol Cancer Res. 2013 Aug;11(8):834-44
pubmed: 23576572
Clin Microbiol Infect. 2009 Sep;15(9):806-12
pubmed: 19702585
Mol Cancer. 2011 Mar 18;10:29
pubmed: 21418558
Nature. 2005 Jun 9;435(7043):834-8
pubmed: 15944708
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
J Infect Dis. 2009 Sep 15;200(6):916-25
pubmed: 19650740
World J Gastroenterol. 2016 Sep 21;22(35):7951-62
pubmed: 27672290
Oncol Res Treat. 2015;38(9):436-40
pubmed: 26405762
N Engl J Med. 2002 Oct 10;347(15):1175-86
pubmed: 12374879
J Genet. 2016 Dec;95(4):991-995
pubmed: 27994199
Nat Immunol. 2008 Aug;9(8):839-45
pubmed: 18645592
PLoS One. 2013;8(4):e60315
pubmed: 23565224
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nucleic Acids Res. 2016 Jan 4;44(D1):D239-47
pubmed: 26590260
Int J Cancer. 2011 Jan 15;128(2):361-70
pubmed: 20333682
Biochim Biophys Acta. 2015 Sep;1852(9):1743-54
pubmed: 26047679
FASEB J. 2013 Dec;27(12):4929-39
pubmed: 23982143
J Cancer Res Ther. 2019 Jan-Mar;15(1):108-114
pubmed: 30880764
J Gastroenterol. 2012 Sep;47(9):988-98
pubmed: 22382634